FDA Antifungal Drug Registration Guide
The OTC topical antifungal monograph, eligible actives and indications, why OTC antifungals can't treat nail fungus, and the registration requirements.
Key Takeaways
- OTC topical antifungals are OTC drugs — under the topical antifungal monograph.
- Indications: athlete's foot, jock itch, ringworm — tolnaftate also for prevention.
- Eligible actives — clotrimazole, miconazole, terbinafine, tolnaftate, and more.
- No nail-fungus claims — the monograph is "not effective on scalp or nails"; that's Rx.
- Vaginal antifungals — a separate monograph, not this one.
- Full OTC apparatus — registration, NDC listing, Drug Facts, cGMP, OMUFA, U.S. Agent.
Why Antifungals Are OTC Drugs
An antifungal is intended to treat a fungal infection — a drug purpose, not a cosmetic one. So OTC topical antifungals are regulated as OTC drugs under the topical antifungal monograph (21 CFR Part 333 Subpart C / OTC Monograph M005), which defines the eligible active ingredients, the conditions they may treat, and the required labeling.
Eligible Actives & What They Treat
| Active ingredient | Monograph indication |
|---|---|
| Clotrimazole | Athlete's foot, jock itch, ringworm |
| Miconazole nitrate | Athlete's foot, jock itch, ringworm |
| Terbinafine hydrochloride | Athlete's foot, jock itch, ringworm |
| Butenafine hydrochloride | Athlete's foot, jock itch, ringworm |
| Tolnaftate | Treatment and prevention of athlete's foot; jock itch, ringworm |
| Undecylenic acid (& undecylenate salts) | Athlete's foot, jock itch, ringworm |
OTC Antifungals Can't Treat Nail Fungus
This is the antifungal trap. The topical antifungal monograph directions explicitly require the statement that the product "is not effective on the scalp or nails." Nail fungus — onychomycosis — is simply not an OTC indication.
- You cannot claim to treat, cure, or clear nail fungus on an OTC topical antifungal — it's an unapproved new drug claim
- Nail-fungus claims are a known enforcement target — FDA has acted against OTC products marketed for nails
- Nail fungus needs a prescription — oral antifungals, or Rx topicals (not the OTC monograph route)
- "Restores healthy nails," "clears nail fungus," etc. — all push the product outside the monograph
Requirements & Drug Facts
- Drug establishment registration — 21 CFR Part 207, with DUNS/FEI (foreign facilities also need a U.S. Agent)
- Labeler code & NDC listing — each product listed in SPL
- Monograph-compliant active — an eligible antifungal at a permitted concentration
- Drug Facts label — active & purpose, uses (the tinea indication), warnings, directions, inactive ingredients — including the "not effective on scalp or nails" statement
- cGMP + OMUFA + annual renewal — quality manufacturing (21 CFR 211), the OTC facility fee, and the Oct–Dec renewal
OTC vs Prescription — and Vaginal Antifungals
- OTC topical (monograph) — athlete's foot, jock itch, ringworm; no NDA needed if compliant
- Prescription antifungals — oral drugs (terbinafine, itraconazole) and Rx topicals for nails/serious infections; require an approved application (NDA/ANDA), not the monograph
- Vaginal antifungals — for vaginal yeast (clotrimazole, miconazole, tioconazole) — a separate vaginal antifungal monograph, still an OTC drug but under different labeling
Get Your Antifungal FDA-Compliant
FDA Registration Assistance handles the OTC drug side of antifungals: drug establishment registration, NDC drug listing (SPL), Drug Facts label and claims review against the topical antifungal monograph (including flagging non-compliant nail-fungus claims), U.S. Agent for foreign firms, and import documentation — so your product is compliant before you manufacture, label, list, import, or sell.
Contact us at info@fdaregistrationassistance.com or call +1 (928) 275-8333 for a quote. An independent compliance firm serving 1,000+ companies across 135+ countries, with 15+ years of experience.
Frequently Asked Questions — Antifungal Drug Registration
1. Do antifungal products require FDA registration?
Yes. OTC topical antifungals are regulated as OTC drugs under the topical antifungal monograph (21 CFR Part 333 Subpart C, now OTC Monograph M005), because treating a fungal infection is a drug claim. So the facility must complete drug establishment registration, each product must be listed with an NDC (SPL), and the product needs a compliant Drug Facts label, cGMP, OMUFA fees, and (for foreign facilities) a U.S. Agent.
2. What conditions can an OTC antifungal treat?
The topical antifungal monograph covers athlete's foot (tinea pedis), jock itch (tinea cruris), and ringworm (tinea corporis). One ingredient (tolnaftate) is also recognized for the prevention of athlete's foot. Those are the OTC indications — a monograph antifungal is labeled to treat those tineas, and its claims have to stay within them.
3. Can an OTC antifungal treat nail fungus?
No. The topical antifungal monograph explicitly states the product "is not effective on the scalp or nails." Nail fungus (onychomycosis) is not an OTC indication, so an OTC topical antifungal cannot claim to treat, cure, or clear nail fungus — doing so is an unapproved new drug claim and a frequent enforcement target. Nail fungus is treated with prescription products (oral antifungals, or Rx topicals). If your product targets nails, it's outside the OTC monograph.
4. Which active ingredients are allowed?
The monograph's eligible actives include clotrimazole, miconazole nitrate, terbinafine hydrochloride, tolnaftate, butenafine hydrochloride, and undecylenic acid (with its undecylenate salts), each at specified concentrations. Your product must use a monograph active at a permitted strength for the labeled tinea indication. An ingredient or concentration outside the monograph means the monograph pathway isn't available and an NDA would be required.
5. Are vaginal antifungals covered by the same monograph?
No — they're separate. OTC vaginal antifungals (for vaginal yeast infections, using ingredients like clotrimazole, miconazole, or tioconazole) fall under a different vaginal antifungal monograph, not the topical (athlete's foot/jock itch/ringworm) monograph. They're still OTC drugs with the same registration/listing/Drug Facts requirements, but the applicable monograph and labeling differ.
6. What does an antifungal Drug Facts label require?
A Drug Facts panel (21 CFR 201.66): active ingredient and purpose (antifungal), uses (the specific tinea indication[s]), warnings, directions, and inactive ingredients. The monograph specifies the directions — clean the affected area and apply a thin layer twice daily; use daily for 4 weeks for athlete's foot and ringworm, or 2 weeks for jock itch — and requires the statement that the product isn't effective on the scalp or nails. The label must match the SPL listing.
7. What are the FDA requirements to sell an OTC antifungal?
Drug establishment registration (21 CFR Part 207) with a DUNS/FEI; a labeler code and NDC drug listing (SPL); a monograph-eligible active at a permitted concentration; a compliant Drug Facts label; cGMP manufacturing (21 CFR 211); OMUFA facility fees; a U.S. Agent for foreign facilities; and annual renewal. It's the standard OTC drug apparatus, with the antifungal monograph governing the actives and claims.
8. Is an OTC antifungal the same as a prescription one?
No. OTC topical antifungals treat superficial skin tineas (athlete's foot, jock itch, ringworm) under the monograph. Prescription antifungals — oral drugs like terbinafine or itraconazole, and Rx topicals for nails — treat more serious or resistant infections (including nail and systemic fungal infections) and require an approved application (NDA/ANDA), not the monograph pathway. Matching your product to the right route is the first classification step.
9. Do foreign antifungal manufacturers need a U.S. Agent?
Yes. A foreign OTC antifungal establishment must complete drug establishment registration and designate a U.S. Agent (21 CFR 207.69) — the U.S.-based contact for FDA communications and inspections. Without a valid, confirmed U.S. Agent the registration isn't complete, and the establishment's products can be refused at the border.
10. What is drug listing / NDC for an antifungal?
Each antifungal product is listed with FDA and assigned a National Drug Code (NDC), submitted in Structured Product Labeling (SPL) format. The listing captures the active ingredient and strength, dosage form, package, and labeling. Registration covers the facility; listing covers each product; both must be accurate and current, and listing errors are a common cause of delays.
11. Does an antifungal need to comply with cGMP?
Yes. As an OTC drug, an antifungal must be manufactured under current Good Manufacturing Practice (21 CFR Part 211), which supports consistent potency and quality. A product not made under cGMP is considered adulterated and can be detained or recalled, regardless of a clean registration and listing.
12. Is there a fee, and does the registration renew?
Yes to both. OTC monograph drug manufacturers — including antifungal makers — pay the annual OMUFA facility fee. And drug establishment registration renews annually, October–December (21 CFR 207.29), with drug listings kept current. A lapse makes the product misbranded and can inactivate the listing, so it's ongoing compliance, not a one-time filing.
13. What are the most common antifungal compliance mistakes?
Claiming to treat nail fungus (the big one — it's outside the monograph); treating an antifungal as a cosmetic; using an ingredient or concentration outside the monograph; non-compliant Drug Facts labeling (missing the "not effective on scalp or nails" statement, wrong directions/duration); skipping establishment registration or NDC listing; and overlooking OMUFA and renewal. Most are caught by matching the product to the monograph before launch.
14. Does registering an antifungal mean it's FDA-approved?
No. Registration identifies the facility, listing identifies the product, and monograph compliance lets you market without an NDA — but none of these is FDA "approval." Claiming an antifungal is "FDA-approved" because it's registered or listed is misbranding. It's compliance, not approval.
15. Can imported antifungal products be detained?
Yes. FDA can detain antifungal imports that appear misbranded, unregistered, unlisted, made with a non-monograph active, or carrying disallowed claims (like nail-fungus claims). A compliant Drug Facts label, an eligible active, clean registration/listing, and a responsive U.S. Agent are what keep shipments moving.
16. How does FDA Registration Assistance help with antifungal products?
We handle the OTC drug side: drug establishment registration, NDC drug listing (SPL), Drug Facts label and claims review against the topical antifungal monograph (including flagging non-compliant nail-fungus claims), U.S. Agent for foreign firms, and import documentation — so your antifungal is compliant before you manufacture, label, list, import, or sell. We're an independent compliance firm serving 1,000+ companies across 135+ countries with 15+ years of experience. Contact info@fdaregistrationassistance.com or +1 (928) 275-8333.
